Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

EVOK stock opened at $4.71 on Friday. The business has a 50-day simple moving average of $4.49 and a two-hundred day simple moving average of $4.93. The company has a market capitalization of $7.02 million, a P/E ratio of -0.43 and a beta of 0.15. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The company had revenue of $2.65 million for the quarter.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.